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Background: Previous studies have documented similar levels of end-of-life symptom
burden for lung cancer and chronic obstructive pulmonary disease (COPD) patients, yet
there has been little comparison of health care utilization during this period. This study
contrasts health care utilization by people with COPD and those with lung cancer in the 12
months prior to death.
Methods: We performed a retrospective cohort study of 1098 patients who died in 2004
with a cause of death recorded as COPD or lung cancer using administrative health data.
Our outcomes of interest included acute, long-term and home care service utilization.
Results: The study population was 42% female with a mean age of 77 years (S.D. ¼ 11). In
the last 12 months of life, decedents with COPD were more likely to be institutionalized in
a LTC setting (41% vs. 12.5%, po0.05) and to receive long-term home care (26% vs. 9.7%,
po0.05), but were much less likely to receive palliative care in hospital (47.6% vs. 5.1%,
po0.001) or at home (37.4% vs. 2.8%, po0.05) than people with lung cancer. In contrast,
decedents with lung cancer made greater use of acute care services than those with COPD
in that they were more likely to be hospitalized (94.2% vs. 80.4%, po0.05) and had longerElsevier Ltd. All rights reserved.
ctive pulmonary disease; ICU, intensive care unit; LTC, long-term care; LOS, length of stay; UCOD,
ultiple cause of death; ICD, International Classification of Diseases; IQR, interquartile range; S.D.,
f variance; CI, confidence interval; OR, odds ratio; VA, veterans affairs.
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D. Goodridge et al.886median LOS (7.0 vs. 5.7 days, po0.05) than those with COPD. No differences in the number
of out-patient physician visits were noted.
Conclusions: Patterns of end-of-life health care utilization differ significantly between
people with lung cancer and those with COPD. Further research is needed to establish need
and determine gaps in services to better address the needs of people dying with COPD.
& 2008 Elsevier Ltd. All rights reserved.Introduction
As the only leading cause of death in the US with an escalating
mortality rate,1 chronic obstructive pulmonary disease (COPD)
is increasingly recognized as a life-limiting illness that imposes
significant symptom burden upon those with advanced disease
and their families. Dyspnea, fatigue, low mood and pain are
experienced by the majority of individuals with COPD in the
last year of life.2 The American College of Chest Physicians’
position statement on palliative care for patients with
cardiopulmonary disease3 affirms that the prevention, relief,
reduction and soothing of symptoms ‘‘without affecting a
cure’’ must be an integral part of standard care.
Unfortunately, attainment of these palliative goals has
remained elusive for many individuals with advanced chronic
respiratory disease. The end-of-life physical and psychosocial
needs of patients with severe COPD have been demonstrated
to match or surpass those experienced by persons with lung
cancer.4–11 Patients with advanced COPD had higher rates of
dyspnea,6 depression and anxiety4; had worse quality of life9;
had fewer drugs prescribed for symptom management10; and
were more likely to have been admitted to an ICU than
people with lung cancer.11 Despite these issues, they received
fewer formal palliative care services.6 Palliative care team
involvement in one controlled trial of outpatients was
documented to improve outcomes related to dyspnea,
anxiety and spiritual well being, but not pain and depres-
sion.12 A meta-analysis by Higginson et al.13 found quantita-
tive support for the effectiveness of palliative care teams in
enhancing end-of-life care.
While the overall aim of therapeutic management at any
stage of COPD is to improve quality of life and manage
symptoms, the end-of-life symptom disparities between
people with COPD and those with lung cancer suggest care
of COPD patients remains sub-optimal. Patients with COPD
generally have limited access to enriched resources available
through palliative care programs, in part because of the
difficulty of prognostication.14 The development of new and
more responsive models of end-of-life care for this population
will be contingent upon understanding current patterns of
health care utilization. This study begins to address this need
through the examination of these utilization patterns for all
individuals who died with either an underlying or multiple
cause of death (MCOD) of COPD or underlying cause of death
(UCOD) of lung cancer in 2004 in one Canadian province.
Methods
Study population and design
This was a retrospective study within the province of
Saskatchewan, Canada (population approximately 1,000,000)using the Saskatchewan Health administrative databases.
The Saskatchewan Health databases15 have been used
previously to conduct large epidemiological studies of
respiratory health.16–18 Subjects who had either lung cancer
(ICD-10 code C34.x) as the UCOD or COPD (ICD-10 code
J44.x) as either the underlying or a multiple cause of death
and died in 2004 were identified. The index date was the
date of death.
This study was submitted to the University of Saskatch-
ewan Behavioural Research Ethics Board, but did not require
ethical approval because of the de-identified nature of the
data.Saskatchewan Health databases
Most residents of Saskatchewan (approximately 99%) have
universal health care coverage provided by Saskatchewan
Health. Exceptions to this are those persons covered by the
federal government including federal inmates, Royal Cana-
dian Mounted Police and Canadian Forces. Registered
Indians are not covered under the provincial drug plan and
are therefore excluded from the present study.
Each person covered by Saskatchewan Health has a
unique identifier that can be used to link the various
databases. Prior to receiving the data from Saskatchewan
Health, the unique identifier was de-identified. The data-
bases provided by Saskatchewan Health included: subject
file, physician services file, physician visits file, hospital
services file, home care file, institutional supportive care
file and the vital statistics file.
The subject file contains information regarding demo-
graphic variables including sex, year of birth, marital status,
area of residence and dates of coverage. The physician
services file includes dates of physician services and fee-for-
service codes (FSCs) for FSCs of interest and the physician
visits file includes the date of the outpatient visit, diagnosis,
location of service and the approved payment amount
for a visit. The hospitalization services file includes
dates of admission and discharge, diagnoses and diagnoses
types, and procedures of interest undertaken during
hospitalization.
The home care file includes dates of admission and
discharge for home care, months eligible for services,
amount of time spent on specific types of home care duties
and costs associated with home care. While health care
coverage is considered universal, clients do pay fees for
home care services. In 2004, Saskatchewan home care
clients paid user fees of $6.25–6.36 per service for the first
10 units of services per month, with the remainder of fees
assessed based on income to an annual maximum of
$375–383.19 Patient receiving palliative care pay no fees
for home care.
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Table 1 Demographic and co-morbidity among subjects
who had lung cancer, COPD, or lung cancer and COPD.
Lung
cancer,
N ¼ 433
COPD,
N ¼ 602
Lung
cancer and
COPD,
N ¼ 63
Age group
p70 years 41.6,y 11.5z 14.3
71–79 years 33.9 25.6 39.7
80–85 years 15.0 23.1 33.3
485 years 9.5 36.9 12.7
Sex
Male 56.4 59.0 63.5
Female 43.6 41.0 36.5
Marital status
Married/common-law 55.9 38.2 44.4
Never married 6.7 9.0 6.3
Separated/divorced 24.2 28.4 23.8
Widowed 13.2 24.4 25.4
Area of residence
Urban 40.4 36.4 46.0
Rural 59.6 63.6 54.0
Co-morbidity
0–1 Condition 68.4 31.7z 58.7
2 Or more conditions 31.6 68.3 41.3
po0.05 between the lung cancer and COPD groups using
the w2 tests for proportions with a Bonferonni correction.
ypo0.05 between the lung cancer group and the lung
cancer and COPD group using the w2 tests for proportions with
a Bonferonni correction.
zpo0.05 between the COPD group and the lung cancer and
COPD group using the w2 tests for proportions with a
Bonferonni correction.
Health care utilization of patients with COPD and lung cancer 887The institutional supportive care home file includes dates
of admission and discharge, program (long-term care (LTC),
temporary care), purpose of temporary care, level of care
and type of facility. Saskatchewan Health provides funding
to cover approximately 77% of overall LTC costs, although an
income-tested resident charge is applied.20 Finally, the vital
statistics file includes the date of death, UCOD and MCODs as
well as the location of death (rural vs. urban).
Operational definitions of outcome measures
Several variables were recoded prior to analysis including
the number of physician visits, number of hospitalizations
and hospitalization length of stay (LOS). These variables
were dichotomized based on evidence from the litera-
ture11,21 as well as intuitively logical points based on
important calculated values from the data such as the
median. The number of physician visits were classified as
424 visits orp24 visits in the year representing an average
of two outpatient visits per month. The number of
hospitalizations was categorized as 42 or p2 hospitaliza-
tions in a year while the mean LOS was categorized as 47
days orp7 days representing a full week in hospital. Finally,
co-morbid conditions were classified based on the number of
conditions as41 orp1 based on the presence or absence of
disease conditions included in the UCOD or MCOD.
Statistical analysis
Statistical analysis was completed using SPSS 15.0. Level of
significance (s) was set at 0.05. The variable of primary
interest was the two-level disease group variable indicating
lung cancer (reference group) or COPD. Comparisons
between the two groups were completed using analysis of
variance (ANOVA) with Scheffe post-hoc tests and w2 tests of
proportion where appropriate. When the assumptions for
these tests were not met, the Kruskal Wallis test (with
multiple Mann–Whitney tests adjusted with Bonferroni
corrections for post-hoc analysis) and Fisher’s Exact tests
were used, respectively.
Associations with specific health care utilization out-
comes were assessed using multiple logistic regression. The
strength of association was measured by the odds ratio (OR)
and 95% confidence intervals (CI). Binary health care
utilization variables were considered outcomes. Interactions
between age group, sex, marital status, area of residence
and co-morbidity with disease group were assessed by the
multiple partial Likelihood Ratio test. When interaction was
significant, a stratified analysis was completed.
Results
In 2004, 1098 beneficiaries of Saskatchewan Health eligible
for prescription drug benefits were identified as having
either lung cancer (n ¼ 483) as their UCOD or COPD
(n ¼ 615) as their underlying (UCOD) or multiple (MCOD)
cause of death. Among those with COPD as their UCOD or
MCOD, 287 (47.7%) had COPD as their UCOD. Diagnoses of
both lung cancer and COPD (n ¼ 63) were reported for 63 of
these decedents, leaving 433 with lung cancer only and 602
with COPD only. Cases with both lung cancer and COPD wereincluded in the initial analyses, but are not reported in this
paper. Approximately, 58% of this population was male with
an average age of 77 years (S.D. ¼ 11 years). Most of the
population lived in rural areas (61.5%), were married or
common-law (45.5%) and had more than one co-morbid
condition (52.2%). The distribution of sex and area of
residence was similar among the disease groups (Table 1).
However, there were statistically significant (po0.001)
differences by age group, marital status and co-morbidity
among the disease groups. Those with only lung cancer were
younger than those with COPD (Table 1). Those with lung
cancer were also more likely to be married or common-law
and less likely to be widowed than the COPD group (Table 1).
Finally, those with COPD were more likely to have more
than one co-morbid condition than those with lung cancer
(Table 1).
In terms of health care utilization in the 12 months prior
to death, there were no statistically significant differences
by disease group for physician visits (Table 2). The COPD
group, however, was less likely to be hospitalized, was
hospitalized less frequently and had shorter LOS than those
in the lung cancer group. Those with COPD were more likely
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Table 2 Health care utilization in the 12 months prior to death among subjects with COPD, lung cancer or lung cancer and
COPD.
Lung cancer,
N ¼ 433
COPD,
N ¼ 602
Lung cancer and
COPD, N ¼ 63
Physician visits
Median number (IQR) 27.00 (22.00) 28.00 (28.00) 25.00 (16.00)
% With 424 56.6 59.8 50.8
Hospitalization
Median average LOS (IQR) 7.00 (8.00) 5.71 (9.58) 5.80 (7.00)
% With mean LOS47 days 48.3 40.2 39.7
Median total LOS (IQR) 22.00 (27.50) 13.00 (31.00) 18.00 (23.00)
% With any hospitalization 94.2,y 80.4 84.1
% With 42 hospitalizations 51.3 37.4 41.3
Institutional care
% With any care 25.9 48.2z 31.7
% With LTC 12.5 41.0z 19.0
% With temporary care 16.9 15.3 15.9
Home care
% With any home care 59.1 46.7 55.6
% With 1 year of home care 9.7,y 26.6 28.6
Palliative care use
% Within hospital (based on diagnosis of palliative care) 47.6 5.1z 27.0
% Within temporary institutional supportive care 12.7 1.3z 6.3
% From home care 37.4 2.8z 28.6
IQR: inter-quartile range; LOS: length of stay; LTC: long-term care.
po0.05 between the lung cancer and COPD groups using the w2 tests for proportions with a Bonferonni correction.
ypo0.05 between the lung cancer group and the lung cancer and COPD group using the w2 tests for proportions with a Bonferonni
correction.
zpo0.05 between the COPD group and the lung cancer and COPD group using the w2 tests for proportions with a Bonferonni
correction.
D. Goodridge et al.888to spend time in an institutional supportive care facility than
the lung cancer group.
While there was no difference in the proportion of
persons spending time in temporary care among the disease
groups, those with COPD were more likely to spend time in a
LTC (Table 2). Any use of home care was least likely in the
COPD group (Table 2). However, home care was significantly
more likely to be used for a full year in the COPD group than
the lung cancer group (Table 2). Finally, the COPD group was
less likely to use palliative care resources provided in the
hospital or home care setting than the lung cancer group
(Table 2).
After adjustment for age group, sex, marital status, area
of residence and co-morbidity, there were no differences
between disease groups for a high number of physician visits
(424) or using any institutional care in the year prior to
death (Table 3). However, as presented in Table 3, those
with COPD were less likely to be hospitalized or use
temporary institutional care (OR ¼ 0.42, 95%CI ¼ 0.25–
0.70; OR ¼ 0.67, 95%CI ¼ 0.45–1.00, respectively), but
more likely to use institutional LTC (OR ¼ 2.01, 95%CI ¼
1.36–2.95). Because there was significant interaction be-
tween disease status and LTC use in relation to any use of
home care and use of home care for a full year, the
multivariate analysis was stratified by LTC use. Among thosewho did not use LTC, those with COPD were significantly
more likely to use home care for a full year compared to
those with lung cancer (Table 4). There was no association
between any home care use and cause of death among those
not using LTC, although there was a trend (p ¼ 0.05) for
those with COPD to be less likely to use home care. Among
those who used LTC, there was no statistically significant
association between cause of death and use of home care for
a full year while there was significant inverse association
between cause of death and any home care use where COPD
decedents were less likely to use home care.Discussion
Our findings demonstrate significant differences in the
health care utilization and trajectory of individuals dying
with lung cancer and COPD during the last 12 months of life.
During this time frame, decedents with COPD were more
likely to be institutionalized for LTC and to receive long-
term home care, but were less likely to receive formal
palliative care services in hospital or at home than people
with lung cancer. In contrast, decedents with lung cancer
made greater use of acute care services than those with
COPD in that they were more likely to be hospitalized, were
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Table 3 Multivariate analysis examining associations between disease status, demographic characteristics and co-
morbidity with physician visits, hospitalization and institutional care (n ¼ 1098).
424 Physician
visits, OR (95% CI)
Any
hospitalization,
OR (95% CI)
Any institutional
care, OR (95% CI)
Any institutional
long-term care,
OR (95% CI)
Any institutional
temporary care,
OR (95% CI)
Disease status
Lung cancer 1.00 1.00 1.00 1.00 1.00
COPD 1.17 (0.87–1.59) 0.43 (0.26–0.72)y 1.15 (0.83–1.60) 2.02 (1.37–2.97)y 0.65 (0.44–0.97)y
Age group
p70 years 1.00 1.00 1.00 1.00 1.00
71–79 years 0.97 (0.68–1.40) 1.04 (0.50–2.15) 1.76 (1.14–2.72)y 1.55 (0.86–2.80) 1.82 (1.08–3.07)y
80–85 years 1.01 (0.68–1.52) 0.44 (0.22–0.87)y 3.96 (2.50–6.27)y 5.02 (2.83–8.91)y 2.37 (1.35–4.16)y
485 years 0.72 (0.48–1.08) 0.24 (0.12–0.47)y 8.89 (5.54–14.25)y 10.66 (6.02–18.88)y 2.38 (1.34–4.25)y
Sex
Male 1.00 1.00 1.00 1.00 1.00
Female 1.18 (0.90–1.55) 0.98 (0.66–1.46) 1.31 (0.98–1.77) 1.30 (0.93–1.82) 1.03 (0.72–1.48)
Marital status
Married/
common-law
1.00 1.00 1.00 1.00 1.00
Never married 0.67 (0.42–1.09) 0.34 (0.18–0.64)y 1.76 (1.04–2.97)y 2.44 (1.37–4.37)y 1.13 (0.61–2.09)
Separated/
divorced
1.24 (0.89–1.72) 0.61 (0.37–1.00) 1.49 (1.04–2.13)y 2.11 (1.41–3.17)y 0.77 (0.49–1.21)
Widowed 0.66 (0.46–0.95)y 0.89 (0.52–1.52) 1.23 (0.83–1.82) 1.44 (0.93–2.21) 0.90 (0.56–1.46)
Area of residence
Rural 1.00 1.00 1.00 1.00 1.00
Urban 1.87 (1.43–2.45)y 1.00 (0.68–1.48) 0.76 (0.57–1.02) 1.03 (0.74–1.42) 0.38 (0.26–0.57)y
Co-morbidity
0–1 Condition 1.00 1.00 1.00 1.00 1.00
2 Or more
conditions
1.50 (1.14–1.97)y 0.93 (0.62–1.40) 1.65 (1.23–2.23)y 1.97 (1.40–2.76)y 1.08 (0.75–1.56)
OR: odds ratio; CI: confidence interval.
Adjusted for all the variables in the table.
ypo0.05.
Table 4 Multivariate analysis examining associations
between disease status with home care use after
stratification by LTC use (n ¼ 1098).
Any home care,
OR (95% CI)
Home care for
full year, OR
(95% CI)
Among those without LTC use
Lung cancer 1.00 1.00
COPD 0.72 (0.51–1.00) 2.92 (1.84–4.65)z
Among those with LTC use
Lung cancer 1.00 1.00
COPD 0.47 (0.24–0.92)y 1.77 (0.73–4.29)
OR: odds ratio; CI: confidence interval.
Adjusted for sex, age group, marital status, area of
residence and co-morbidity after stratification by use of
institutional LTC in the 12 months prior to death.
ypo0.05.
zpo0.001.
Health care utilization of patients with COPD and lung cancer 889hospitalized more frequently and had longer LOS than those
with COPD. Fewer than half of the lung cancer patients at
the end of life made use of palliative care services in
hospital or at home, in spite of the documented effective-
ness of this intervention in improving care in cancer
populations.12,13
The functional burden imposed by a debilitating, chronic
illness such as COPD is likely reflected in the significantly
higher rates of long-term institutional and home care
utilization among those with COPD compared with people
who had lung cancer. In the final year of life, 41% of those
with a diagnosis of COPD were functionally compromised to
the point of requiring long-term institutional supportive
care for a full year. Several recent reports have documented
that institutionalized residents of LTC facilities used
relatively few services from other branches of the health
care system, at the end of life,21,22 possibly (and hopefully)
because palliative care needs were being met within this
system.22 Both strengths and shortcomings have been
identified regarding the palliative care provided in the LTC
setting23,24 and further exploration of this issue is needed.
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D. Goodridge et al.890While significantly more persons with lung cancer received
any type of home care in the last year of life than those with
COPD, the long-term nature of home care support for people
with COPD reflects the ongoing needs of this population.
While there has been some suggestion that individuals
with advanced chronic illness make high use of acute care
resources at the end of life,25 we did not find this to be the
case in this sample. Decedents with COPD, despite the
presence of increased co-morbid disease, were less likely to
be hospitalized, were hospitalized less often and had shorter
LOS than those with lung cancer. There was no difference in
the number of outpatient physician visits by patients with
COPD and those with lung cancer, although the median
number of physician visits25–28 was much higher in our
sample than the 1.87–2.36 visits reported by Au et al.11
Very few patients who died with COPD utilized palliative
care services that were available in acute care hospitals
(5.1%) or home care settings (2.8%) compared to those with
lung cancer (acute care 47.6%; home care 37.4%). Possible
explanations for this difference may include diverse factors
such as provider failure to recognize the imminent death of
patients with COPD, the perception that palliative care
services were available only to cancer patients, the
assumption that the care already being provided was
adequate and appropriate or they were receiving palliative
care while institutionalized for LTC (a service not captured
in the administrative data). Lack of utilization of formal
palliative care services meant that the majority of dece-
dents with COPD did not benefit from the symptom
management expertise and consistent approach of a
palliative care interdisciplinary team, in spite of documen-
tation of a high symptom burden among people with
advanced COPD.4–9 Several authors have suggested that
comprehensive end-of-life services are best triggered by
recognition that ‘‘dying this year would not be a surprise’’,
rather than by diagnosis26 or by a 6-month prognosis.27
There is a growing call in the literature for palliative care
services focusing on quality of life and symptom manage-
ment to be offered in tandem with the crisis intervention
model often seen in the management of patients with
chronic illness.27,28
This study was limited by the constraints inherent in using
an administrative database, such as potential inaccuracy of
coding and lack of information on areas of interest such as
ICU and palliative care services provided in LTC of institu-
tional care homes. The administrative data represent one
Canadian province only and may have limited general-
izability because of regional variation in practice. We also
did not have access to data on the stage of lung cancer nor
to spirometry results to assess the presence or severity of
COPD nor to symptom reports from either group. Further,
the data analyzed in this report do not allow for assessment
of the quality of life, appropriateness or adequacy of care to
those who died with either lung cancer or COPD. Data were
not obtained on those with an MCOD of lung cancer without
an UCOD of COPD because it was anticipated that there
would be few people in this category. In order to explore a
potential bias by not including those with an MCOD of lung
cancer, we also compared those with an UCOD of lung cancer
to those with an UCOD of COPD, excluding those with COPD
as a MCOD, and found that the patterns of association and
their interpretations were identical to those found in theanalysis presented herein, with the associations being
typically stronger (data not shown).
The strengths of this study included access to 12 months
of comprehensive health care data for the entire cohort of
decedents in a geographically large and diverse province in
2004, including acute care and home care. The dataset was
robust, with little missing data, and captured care that
occurred across multiple settings, thus reflecting the nature
of treatment provided.
People dying with COPD are well recognized to suffer
from a higher level of unaddressed physical and psychosocial
symptom burden than those with lung cancer.4–9 Patterns of
health care utilization during the last 12 months of life differ
markedly between those dying with COPD and lung cancer.
Palliative care services in hospital and home care are not
well-utilized by those dying from COPD, suggesting the need
for examination of the quality of end-of-life care received
by this group. If deficits are identified, either a reconfigura-
tion of existing services or the development of a new model
of care capable of more adequately addressing end-of-life
needs may be in order. Additional investigation into the
unique needs of people dying from non-malignant diseases,
including quality of life, the appropriateness of in-hospital
deaths, access to supportive care resources and the
adequacy of pain and other symptom management, will be
critical to achieving this goal.
Conflict of interest statement
None of the authors have a conflict of interest to declare in
relation to this work.
Acknowledgment
Project funded by a Saskatchewan Health Research Founda-
tion New Investigator Establishment Grant.
References
1. Jemal A, Ward E, Hao Y, et al. Trends in the leading cause of
death in the United States, 1970–2002. JAMA 2005;294:1255–7.
2. Elkington H, White P, Addington-Hall J, Higgs R, Edmonds P. The
health care needs of chronic obstructive pulmonary disease
patients in the last year of life. Pall Med 2005;19:485–91.
3. Selecky PA, Eliasson CA, Hall RI, and the ACCP Ethics
Committee, et al. Palliative and end-of-life care for patients
with cardiopulmonary disease. Chest 2005;128:3599–610.
4. Gore JM, Brophy CJ, Greenstone MA. How well do we care for
patients with end stage chronic obstructive pulmonary disease
(COPD)? A comparison of palliative care and quality of life in
COPD and lung cancer. Thorax 2000;55:1000–6.
5. Claesens MT, Lynn J, Zhensao Z, et al. Dying with lung cancer or
chronic obstructive pulmonary disease: insights from SUPPORT.
J Am Ger Soc 2000;48:S146–53.
6. Edmonds P, Karlsen S, Kahn S, et al. A comparison of the
palliative care needs of patients dying from chronic respiratory
diseases and lung cancer. Pall Med 2001;15:287–95.
7. Skilbeck J, Mott L, Page H, et al. Palliative care in chronic
obstructive airways disease: a needs assessment. Pall Med
1998;12:245–54.
8. Tranmer JE, Heyland D, Dudgeon D, et al. Measuring the
symptom experience of seriously ill cancer and non-cancer
ARTICLE IN PRESS
Health care utilization of patients with COPD and lung cancer 891patients near the end of life with the Memorial Symptom
Assessment Scale. J Pain Symptom Manage 2003;25:420–9.
9. Fan VS, Curtis RJ, Tu SP, et al. Using quality of life to predict
hospitalization and mortality in patients with obstructive lung
disease. Chest 2002;122:429–36.
10. McKinley RK, Stokes T, Exley C, Field D. Care of people dying
with malignant and cardiorespiratory disease in general
practice. Br J Gen Pract 2004;54:909–13.
11. Au DH, Udris EM, Fihn SD, et al. Differences in health care
utilization at the end of life among patients with Chronic
Obstructive Pulmonary Disease and patients with lung cancer.
Arch Intern Med 2006;166:326–31.
12. Rabow MW, Dibble SL, Pantilat SZ, McPhee SJ. The comprehen-
sive care team: a controlled trial of outpatient palliative
medicine consultation. Arch Intern Med 2004;164:83–91.
13. Higginson I, Finlay I, Goodwin D, Hood K, Edwards AGK, Cook A,
et al. Is there evidence that palliative care teams alter end-of-
life experiences for patients and their caregivers? J Pain
Symptom Manage 2003;25:150–68.
14. Hansen-Flaschen J. Chronic obstructive pulmonary disease: the
last year of life. Respir Care 2004;49:90–8.
15. Downey W, Stang MR, Beck P, Osei W, Nichol J. Health services
databases in Saskatchewan. In: Strom BL, editor. Pharmacoe-
pidemiology. 4th ed. Chichester: Wiley; 2005. p. 295–310.
16. Senthilselvan A, Lawson JA, Rennie DC, et al. Stabilization of an
increasing trend in physician-diagnosed asthma prevalence in
Saskatchewan, 1991–1998. Chest 2003;124:438–48.
17. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled
corticosteroids and the prevention of death from asthma. N
Engl J Med 2000;343(5):332–6.18. Spitzer W, Suissa S, Ernst P, et al. The use of beta-agonists and
the risk of death and near death from asthma. N Engl J Med
1992;326(8):501–6.
19. Hollander M. Saskatchewan Health, Community Care Branch
Home Care program review. Victoria, BC: Hollander Analytical
Services Ltd.; 2006.
20. Marchildon G, O’Fee K. Health care in Saskatchewan: an
analytical profile. Regina, SK: Saskatchewan Institute of Public
Policy; 2007.
21. Dy SM, Wolff JL, Frick KD. Patient characteristics and end-of-
life health care utilization among Medicare beneficiaries in 1989
and 1999. Med Care 2007;45:926–30.
22. Canadian Institute for Health Information (CIHI). Health care
use at the end of life in Western Canada. Ottawa, Ont., 2007.
23. Vohra J, Brazil K, Szala-Meneok K. The last word: family
members’ description of end-of-life care in long-term care
facilities. J Pall Care 2006;22:33–9.
24. Goodridge D, Bond J, Cameron C, McKean E. End-of-life care in
a nursing home: a study of family, nurse and health care aide
perspectives. Int J Pall Nurs 2005;11:170–7.
25. Rocker G, Heyland D. New research initiatives in Canada for
end-of-life and palliative care. CMAJ 2003;169:300–1.
26. Murray SA, Boyd K, Kendall M, Worth A, Benton TF, Clausen H.
Dying of lung cancer or cardiac failure: prospective qualitative
interview study of patients and their carers in the community.
BMJ 2002;325:929–37.
27. Murtagh E, Preston M, Higginson I. Patterns of dying: palliative
care for non-malignant diseases. Clin Med 2004;4:39–44.
28. Murray SA, Kendall M, Boyd K, Sheikh S. Illness trajectories and
palliative care. BMJ 2005;330:1007–11.
